Company Overview and News

 
CTGO / Contango Ore, Inc. FORM 10-K (Annual Report)

2018-08-30 sec.gov
conta20170630_10k.htm UNITED STATES
CTGO

10
Progress in Mines to Aid Royal Gold Amid Water Supply Woes

2018-08-22 zacks
On Aug 21, we issued an updated research report on Royal Gold, Inc. (RGLD - Free Report) . The company is poised to gain from improved production and progress in new mines. Its focus on acquisitions and strong cash flow position also bode well. However, inadequate water supplies and lower processing rates at Mount Milligan might impede the company’s near-term growth. Let’s illustrate the factors in detail.
AGCBF RGLD CTGO AGC GSS GG CE RGL GSC

1
Royal Gold, Inc. (RGLD) CEO Tony Jensen on Q4 2018 Results - Earnings Call Transcript

2018-08-10 seekingalpha
Good day, everyone, and welcome to the Royal Gold 2018 Full-Year and Fourth Quarter Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions]. After today’s presentation, there will be an opportunity to ask questions [Operator Instructions]. And please note that today’s event is being recorded.
RGLD CTGO NGD NGDAF NGD RGL GSC

2
CTGO / Contango Ore, Inc. / Gillen Donald - SC 13D/A (Activist Investment)

2018-07-02 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CTGO

2
CTGO / Contango Ore, Inc. / Gillen Donald - SC 13D/A (Activist Investment)

2018-07-02 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CTGO

2
CTGO / Contango Ore, Inc. FORM 10-Q (Quarterly Report)

2018-05-10 sec.gov
conta20170120_10q.htm UNITED STATES SECURITIES AND EXCH
CTGO

24
Royal Gold's (RGLD) CEO Tony Jensen on Q3 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
Good day. And welcome to the Royal Gold Fiscal 2018 Third Quarter Conference Call. All participants will be in listen-only mode [Operator Instructions]. After today’s presentation, there will be an opportunity to ask questions [Operator Instructions]. Please note this event is being recorded.
RGLD CTGO NGD NGDAF NGD RGL GSC

2
CTGO / Contango Ore, Inc. CONTANGO ORE, INC. 8-K (Current Report)

2018-04-25 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
CTGO

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 21077F100